1. Volume 376, Issue 9749, Pages 1329-1337 (October 2010)
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial 
Dr Sheena McCormack, MSc, Prof Gita Ramjee, PhD, Anatoli Kamali, MSc, Prof Helen Rees, MRCGP, Angela M Crook, PhD, Mitzy Gafos, MSc, Ute Jentsch, PhD, Prof Robert Pool, PhD, Maureen Chisembele, MBBS, Saidi Kapiga, MD, Richard Mutemwa, MD, Andrew Vallely, PhD, Thesla Palanee, PhD, Yuki Sookrajh, MBChB, Prof Charles J Lacey, MD, Prof Janet Darbyshire, MSc, Prof Heiner Grosskurth, PhD, Albert Profy, PhD, Prof Andrew Nunn, MSc, Richard Hayes, DSc, Prof Jonathan Weber, PhD 
The Lancet 
Volume 376, Issue 9749, Pages (October 2010)
DOI: /S (10)
Copyright © 2010 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*1564 participants were in follow-up at Feb 14, 2008.
The Lancet  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

3. Figure 2
Adherence to condom and gel use, overall and by research centre
(A) Reported condom use, with or without gel use. (B) Reported gel use, with or without condom use. (C) Reported gel use in unprotected sex (no condom used) participants were enrolled in Durban, South Africa; 2499 in Johannesburg, South Africa; 840 in Masaka, Uganda; 1146 in Mwanza, Tanzania; 1177 in Africa Centre, South Africa; and 1332 in Mazabuka, Zambia.
The Lancet  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions